Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial-Reference-Cited by-同舟云学术

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Published:2016-04 Issue:4 Volume:17 Page:452-463
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kim Dong-Wan,Mehra Ranee,Tan Daniel S W,Felip Enriqueta,Chow Laura Q M,Camidge D Ross,Vansteenkiste Johan,Sharma Sunil,De Pas Tommaso,Riely Gregory J,Solomon Benjamin J,Wolf Jürgen,Thomas Michael,Schuler Martin,Liu Geoffrey,Santoro Armando,Sutradhar Santosh,Li Siyu,Szczudlo Tomasz,Yovine Alejandro,Shaw Alice T

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

2. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance;Song;Acta Pharm Sin B,2015

3. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive;Malik;Clin Cancer Res,2014

4. Crizotinib in ROS1-rearranged non-small-cell lung cancer;Shaw;N Engl J Med,2014

Cited by 342 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for lung cancer;Pathology - Research and Practice;2024-02

2. Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management;Cellular Signalling;2024-01

3. Somatic mutation: Pharmacogenomics in oncology care;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

4. Management strategies for intracranial progression in ALK-positive non-small cell lung cancer: a real-world cohort study;Journal of Neuro-Oncology;2023-12

5. First-line treatment option for patients with ALK-positive metastatic NSCLC;Meditsinskiy sovet = Medical Council;2023-11-23